GH Research PLC (GHRS) Form 6-K — May 14, 2026
GH Research PLC reported its first quarter 2026 financial results, with a net loss of $19.0 million, or $0.31 loss per share, compared to a net loss of $10.8 million, or $0.19 loss per share, in the same quarter of 2025. The company's cash, cash equivalents, and marketable securities stood at $267.3 million as of March 31, 2026, a slight decrease from $280.7 million as of December 31, 2025. Research and development expenses increased by $4.5 million to $12.4 million for the quarter ended March 31, 2026, primarily due to increased technical and clinical development expenses and employee expenses.
Key figures
- Eps
- -0.31
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -18,967
- Total Debt
- 11,890
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 275,267
- Cash Position
- 267,325
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 62,052,506
- Foreign Exchange Loss
- 2,329
- Net Cash Proceeds April2026
- 111,200
- Research And Development Expenses
- 12,379
- General And Administrative Expenses
- 6,370
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.